Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05434234 · ClinicalTrials.gov registry record · Phase 1

A Study of YL201 in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumor, sponsored by MediLink Therapeutics (Suzhou) Co..

Recruiting
Registry status
Phase 1
Development phase
312
Enrollment target
20
Study locations

NCT05434234 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by MediLink Therapeutics (Suzhou) Co.. The registered enrollment target is 312 participants, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (63% higher). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05434234, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by MediLink Therapeutics (Suzhou) Co..

RECRUITING
Registry status
Phase 1
Development phase
312 participants
Enrollment target
20
Study locations

Study Summary

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.

Conditions Studied

Advanced Solid Tumor

Interventions

  • DRUG YL201
  • DRUG YL201 and atezolizumab

Study Locations (20)

Texas

  • 014 - Houston
  • 015 - Irving
  • 013 - San Antonio
  • 016 - Tyler

California

  • 002 - Fair Oaks
  • 001 - La Jolla

Michigan

  • 006 - Ann Arbor
  • 007 - Detroit

Washington

  • 018 - Spokane
  • 019 - Tacoma

Colorado

  • 003 - Lone Tree

District of Columbia

  • 004 - Washington D.C.

Massachusetts

  • 005 - Boston

Missouri

  • 008 - St Louis

Trial Details

FieldValue
Enrollment Target 312 participants
Start Date 2022-05-25
Est. Completion 2027-10-06
Phase Phase 1

Sponsor

MediLink Therapeutics (Suzhou) Co.

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05434234

The ClinicalTrials.gov registry entry for NCT05434234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (63% higher). The listed sponsor is MediLink Therapeutics (Suzhou) Co., which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which YL201 is the first listed.

NCT05434234 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Texas, California, Michigan.

Frequently Asked Questions

What is clinical trial NCT05434234 about?

NCT05434234 is a clinical study titled "A Study of YL201 in Patients With Advanced Solid Tumors". This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohor...

What is the current status of trial NCT05434234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 312 participants. The study started on 2022-05-25. Estimated completion is 2027-10-06.

What conditions does trial NCT05434234 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT05434234?

The interventions under investigation include: YL201 (DRUG), YL201 and atezolizumab (DRUG).

Who is sponsoring clinical trial NCT05434234?

This trial is sponsored by MediLink Therapeutics (Suzhou) Co., which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05434234 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.